NEW!

Hypercholesterolaemia is a well-established risk factor for developing cardiovascular disease (CVD). Globally, hypercholesterolaemia is estimated to cause 2.6 million deaths and 29.7 million disability-adjusted life years. Recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as an important regulator of cholesterol metabolism. Evidence suggests that individuals with reduced PCSK9 activity – whether due to genetic polymorphism or administration of a PCSK9 inhibitor – have lower cholesterol levels and a reduced risk of CVD. This video module discusses findings from recent clinical trials of PCSK9 inhibitors, while simultaneously reviewing current recommendations concerning the use of PCSK9 inhibitors for the treatment of hypercholesterolaemia.

Presenter: Prof.Dr Brian A.Ference

                Professor and Director of Research in Translational Therapeutics

                Executive Director, Centre for Naturally Randomized Trials

                University of Cambridge

• Lecture
• Q&A session

Who should participate:
• Doctors

NOTE :

Terms & Conditions: 

■ Participants must obtain a minimum score of 8/10 (80%) to be awarded 1 point. 
■ MIMS Education and MIMS Medica shall not be responsible or liable for the outcome of your CPD points

Please watch the video before attempting the assessment questions.

To play this video, you are required to have a media player such as Windows Media Player (PC), QuickTime (MAC) or another third party media player.